What does this research mean for the field?

Sacituzumab govitecan demonstrates comparable overall survival and progression-free survival outcomes in patients with metastatic triple-negative breast cancer previously treated with pembrolizumab compared to those treated with chemotherapy. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

Evaluate sacituzumab govitecan outcomes based on prior pembrolizumab therapy in metastatic triple-negative breast cancer.

February 22, 2026Clinical Cancer Research

Abstract PS5-03-08: Effectiveness of sacituzumab govitecan in later-line treatment of mTNBC: real-world evidence from Poland, Czech Republic, and Slovakia according to prior first-line pembrolizumab use

View Full Paper

Ask AI

Bookmark

Authors

JŻJustyna Żubrowska MKMarcin Kubeczko MPMałgorzata Pieniążek

Discussion

Member takes

Overview

Real-world evidence evaluates sacituzumab govitecan outcomes in metastatic triple-negative breast cancer, indicating prior immunotherapy impact is clinically relevant.

Key Points

Evaluate sacituzumab govitecan outcomes based on prior pembrolizumab therapy in metastatic triple-negative breast cancer.
Conducted a retrospective analysis across 18 oncology centers from August 2021 to May 2025.
Stratified patients by previous first-line pembrolizumab exposure according to KEYNOTE-355 guidelines.
Assessed outcomes included progression-free survival, overall survival, objective response rate, and disease control rate.
302 women included; 12.6% had prior anti-PD-1 therapy.
Median overall survival was 10.74 months in the anti-PD-1 group and 11.43 months in chemotherapy group.
No significant differences in progression-free survival, response rates, or toxicity profiles between the groups.

Cite This Study

Żubrowska et al. (2026) studied this question.

synapsesocial.com/papers/699a9e20482488d673cd48b5 https://doi.org/10.1158/1557-3265.sabcs25-ps5-03-08

View Full Paper

Ask AI

Bookmark

February 22, 2026Clinical Cancer Research

Abstract PS5-03-08: Effectiveness of sacituzumab govitecan in later-line treatment of mTNBC: real-world evidence from Poland, Czech Republic, and Slovakia according to prior first-line pembrolizumab use

View Full Paper

Ask AI

Bookmark

Authors

JŻJustyna Żubrowska MKMarcin Kubeczko MPMałgorzata Pieniążek

Discussion

Member takes

Overview

Real-world evidence evaluates sacituzumab govitecan outcomes in metastatic triple-negative breast cancer, indicating prior immunotherapy impact is clinically relevant.

Key Points

Evaluate sacituzumab govitecan outcomes based on prior pembrolizumab therapy in metastatic triple-negative breast cancer.
Conducted a retrospective analysis across 18 oncology centers from August 2021 to May 2025.
Stratified patients by previous first-line pembrolizumab exposure according to KEYNOTE-355 guidelines.
Assessed outcomes included progression-free survival, overall survival, objective response rate, and disease control rate.
302 women included; 12.6% had prior anti-PD-1 therapy.
Median overall survival was 10.74 months in the anti-PD-1 group and 11.43 months in chemotherapy group.
No significant differences in progression-free survival, response rates, or toxicity profiles between the groups.

Cite This Study

Żubrowska et al. (2026) studied this question.

synapsesocial.com/papers/699a9e20482488d673cd48b5 https://doi.org/10.1158/1557-3265.sabcs25-ps5-03-08

View Full Paper

Ask AI

Bookmark